{"protocolSection":{"identificationModule":{"nctId":"NCT06131385","orgStudyIdInfo":{"id":"SWMU-2023-12"},"organization":{"fullName":"The Affiliated Hospital Of Southwest Medical University","class":"OTHER"},"briefTitle":"Registration of Intravenous Thrombolysis for Acute Ischemic Stroke in Southwestern China（IVTIS）","officialTitle":"Registration of Intravenous Thrombolysis for Acute Ischemic Stroke in Southwestern China（IVTIS）","acronym":"IVTIS"},"statusModule":{"statusVerifiedDate":"2023-11","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-11-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2045-12-15","type":"ESTIMATED"},"completionDateStruct":{"date":"2046-05-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-11-09","studyFirstSubmitQcDate":"2023-11-09","studyFirstPostDateStruct":{"date":"2023-11-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-11-26","lastUpdatePostDateStruct":{"date":"2023-11-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Zhengzhou Yuan","investigatorTitle":"Deputy Director of Stroke Center","investigatorAffiliation":"The Affiliated Hospital Of Southwest Medical University"},"leadSponsor":{"name":"Zhengzhou Yuan","class":"OTHER"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study aims to observe the safety and effectiveness of intravenous thrombolysis for acute ischemic stroke in real-world clinical practice.","detailedDescription":"IVTIS is a prospective, real-world registry lasting for 22 years. A total of 3000 patients with intravenous thrombolysis will be enrolled。"},"conditionsModule":{"conditions":["Stroke, Acute"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":3000,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Acute ischemic stroke treated with intravenous thrombolysis","description":"All of acute ischemic stroke patients who treated with intravenous thrombolysis.","interventionNames":["Drug: intravenous thrombolysis"]}],"interventions":[{"type":"DRUG","name":"intravenous thrombolysis","description":"Intravenous thrombolysis using thrombolytic drugs such as ateplase and teneplase.","armGroupLabels":["Acute ischemic stroke treated with intravenous thrombolysis"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"modified Rankin Scale (mRS) score","description":"Ordinal distribution of mRS at 90±7 days; modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)","timeFrame":"90±7 days"}],"secondaryOutcomes":[{"measure":"Excellent functional outcome","description":"Proportion of subjects with mRS 0-1 at 90±7 days.","timeFrame":"90±7 days"},{"measure":"Good functional outcome","description":"Proportion of subjects with mRS 0-2 at 90±7 days.","timeFrame":"90±7 days"},{"measure":"mRS 0-3","description":"Proportion of subjects with mRS 0-3 at 90±7 days.","timeFrame":"90±7 days"},{"measure":"Change of National Institutes of Health Stroke Scale (NIHSS)","description":"Change of National Institutes of Health Stroke Scale (NIHSS, a scale between 0 and 42 on which higher scores indicate more severe neurologic deficits) from baseline to 24 hours.","timeFrame":"24 hours"},{"measure":"Change of National Institutes of Health Stroke Scale (NIHSS)","description":"Change of National Institutes of Health Stroke Scale (NIHSS, a scale between 0 and 42 on which higher scores indicate more severe neurologic deficits) from baseline to 7 days.","timeFrame":"7 days"},{"measure":"Symptom-to-thrombolysis time","description":"Time from onset of symptoms to thrombolytic therapy.","timeFrame":"24 hours"},{"measure":"Door-to-Needle Time","description":"Time from the arrival of stroke patient in emergency to initiation of thrombolysis therapy.","timeFrame":"24 hours"},{"measure":"Incidence of clinically significant intracranial hemorrhage","description":"Incidence of sICH (Heidelberg criteria) measured at 36 hours","timeFrame":"36 hours"},{"measure":"Incidence of any intracranial hemorrhage","description":"Incidence of any intracranial hemorrhage (Heidelberg criteria) measured at 36 hours","timeFrame":"36 hours"},{"measure":"All-cause mortality","description":"All-cause mortality at 90±7 days","timeFrame":"90±7 days"},{"measure":"Complications related to intravenous thrombolysis","description":"Complications related to intravenous thrombolysis during hospitalization","timeFrame":"up to 7 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient was diagnosed with acute ischemic stroke and received intravenous thrombolysis.\n\nExclusion Criteria:\n\n* No additional exclusion criteria.","sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"],"studyPopulation":"Patients with acute ischemic stroke who received intravenous thrombolysis will be included in the study and no additional exclusion criteria have been set.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Zhengzhou Yuan, MD","role":"CONTACT","phone":"+868303165661","email":"coneuro@163.com"}],"overallOfficials":[{"name":"Zhengzhou Yuan","affiliation":"Department of Neurology, Affiliated Hospital of Southwest Medical University, Lu","role":"STUDY_CHAIR"}],"locations":[{"facility":"Affiliated Hospital of Southwest Medical University","status":"RECRUITING","city":"Luzhou","zip":"646000","country":"China","contacts":[{"name":"Zhengzhou Yuan","role":"CONTACT","phone":"+868303165661"}]}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}